Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics is benefiting from a major de-risking milestone as Medicare has begun paying the full expected rate of $1,938 per EsoGuard test, far above the company’s Q2’26 realized ASP of about $530, which could materially lift revenue per test and unlock wider commercial coverage. The recent $15 million financing also strengthens the balance sheet, while third-party validation from Concert’s coverage policy, growing commercial payor dialogue, and support from major GI guidelines reinforce the credibility of EsoGuard and EsoCheck as a differentiated, minimally invasive solution to a large unmet screening need. With a defined target population of GERD patients at risk for esophageal adenocarcinoma, strong reported test performance, and a market opportunity estimated in the tens of billions for U.S. men alone, the company’s reimbursement and adoption trajectory supports a constructive fundamental outlook.

Lucid Diagnostics is constrained by a reimbursement-dependent commercialization model, with its attractive Medicare payment rate for EsoGuard/EsoCheck not yet active or billable until Palmetto GBA’s MolDx issues an LCD, creating meaningful uncertainty around timing and adoption. The lowered 2027 revenue estimate to $23 million from $40 million and the 2026 estimate to $6.1 million from $10 million underscore a slower-than-expected volume ramp, while 2028 revenue of $55 million and ~47,000 EsoGuard tests still imply a relatively modest scale for a commercial-stage company. Beyond reimbursement, the outlook is pressured by early-stage commercial execution, balance sheet and liquidity risk, clinical utility study risk, intellectual property risk, competition, and manufacturing challenges, all of which could limit durable revenue generation.